Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004212 · ClinicalTrials.gov registry record · Phase 1
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004212 is a Phase 1 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00004212, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid tumors or lymphomas that have not responded to previous therapy.
Interventions
- BIOLOGICAL filgrastim
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-09 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004212
The ClinicalTrials.gov registry entry for NCT00004212 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which filgrastim is the first listed.
NCT00004212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004212 about?
NCT00004212 is a clinical study titled "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid tumors or lymphomas that have not responded to previous therapy.
What is the current status of trial NCT00004212?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-09. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00004212?
The interventions under investigation include: filgrastim (BIOLOGICAL), exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00004212?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.